Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-204 in R/R classical Hodgkin lymphoma

John Kuruvilla • 26 May 2020
ASCO 2020
Hodgkin Lymphoma Pembrolizumab
KEYNOTE-204

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, details the results of the KEYNOTE-204 study (NCT02684292) which aimed to determine the benefit of pembrolizumab against brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from John Kuruvilla

The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
0:54
The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
John Kuruvilla • 19 Jun 2025
Exciting advances in the lymphoma treatment landscape: BTK degraders
1:01
Exciting advances in the lymphoma treatment landscape: BTK degraders
John Kuruvilla • 19 Jun 2025
The safety of alloSCT following pembrolizumab treatment in R/R HL
1:11
The safety of alloSCT following pembrolizumab treatment in R/R HL
John Kuruvilla • 19 Jun 2025
Evolving treatment landscape of MCL
Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals